A lack of confidence within the Johnson & Johnson vaccine could carry a specific price.
The vaccine has been greeted warmly by many well being staff as a result of it requires only a single shot, not like those from Moderna or Pfizer-BioNTech, and is less complicated to retailer than another vaccines. It’s particularly helpful for hard-to-reach or transient populations.
“There isn’t a doubt in my thoughts that there are teams for whom this vaccine is of profit,” Dr. Offit mentioned, “that means that they’re extra prone to get this vaccine than the opposite vaccines, whether or not it’s due to the place they reside, or as a result of they’re homebound, or it’s onerous to get a second dose.”
If that adjustments, he mentioned, “then you will have in all probability elevated a uncommon threat above a way more widespread threat, and also you’ve performed hurt.”
In clearing the way in which for the vaccine’s use, the E.U.’s drug regulator, the European Medicines Company, mentioned the blood clots, which have been reported in a really small group of individuals, are “very comparable” to these related to the AstraZeneca vaccine.
The E.M.A.’s advice shouldn’t be binding, however it’s the first indication of what would possibly occur subsequent with the European rollout of the Johnson & Johnson vaccine.
The company mentioned that authorities in particular person E.U. member states ought to resolve proceed, making an allowance for their explicit case load and vaccine availability. Poland is the one E.U. nation that defied the corporate’s steerage and went forward and administered some Johnson & Johnson doses over the previous week.